Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DGT-SM-Cancer2
- Development stage
- Preclinical
- Lead developer
- dGenThera
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
01
Overview
DGT-SM-Cancer2 is an undisclosed small-molecule targeted radiotherapeutic being developed by dGenThera. It is currently in the lead optimization stage of preclinical development. The drug is designed to target specific membrane transporters that are overexpressed in a particular, undisclosed cancer type (referred to as "Cancer 2"). By binding to these transporters, the small molecule delivers a radioactive payload directly to the tumor cells, providing localized radiation therapy while minimizing systemic exposure and off-target toxicity. The specific identity of the transporter target and the radioactive isotope used in this candidate have not been publicly disclosed.
02
Targets
SNAP25 (Synaptosome-associated protein 25)
Beyond the preview
Go deeper on DGT-SM-Cancer2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DGT-SM-Cancer2.